Medtronic Pushes Completion Of Pivotal Renal Denervation Trial To Late 2022
Executive Summary
The company announced that results from the pivotal SPYRAL HTN-ON MED trial of its Symplicity renal denervation system will not be available until the trial completes enrollment next year. The company previously expected to be able to present favorable interim results from the trial in November.
You may also be interested in...
Cardiovascular Catch-Up: ACC Brings Encouraging Renal Denervation And TAVR Data For Medtronic
Medtech Insight’s Cardiovascular Catch-Up highlights recent news and insights from cardiovascular device companies – big and small – from the last few weeks. This edition focuses on news from the recent American College of Cardiology Scientific Sessions.
Cardiovascular Catch-Up: Medtronic And Edwards Make Headlines At TCT Conference
The first half of November was full of cardiovascular device news, led by clinical trial results from renal denervation and transcatheter aortic valve trials presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference.
Cardiovascular Catch-Up: Spring Brings Bloom Of New Clinical Trial Results And Launches
April and May were full of cardiovascular professional society conferences, yielding important new research results along with announcements of major new clinical trials. Here are a few of the highlights.